menu
    • menu
    [{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"INDIA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Bumetanide","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Stalicla","sponsor":"Firefly Neuroscience","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Small molecule","year":"2023","type":"Partnership","leadProduct":"Ibudilast","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"Stalicla","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Stalicla \/ Firefly Neuroscience","highestDevelopmentStatusID":"6","companyTruncated":"Stalicla \/ Firefly Neuroscience"},{"orgOrder":0,"company":"Stalicla","sponsor":"SPRIM Global Investments","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Small molecule","year":"2024","type":"Series B Financing","leadProduct":"Ibudilast","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"Stalicla","amount2":0.02,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"Stalicla \/ SPRIM Global Investments","highestDevelopmentStatusID":"6","companyTruncated":"Stalicla \/ SPRIM Global Investments"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Bumetanide","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd \/ Not Applicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Bumetanide","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd \/ Not Applicable"},{"orgOrder":0,"company":"Corstasis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Bumetanide","moa":"Sodium-potassium ATPase pump","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Corstasis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Corstasis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Corstasis Therapeutics \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Bumetanide

    Menu

    Bumetanide

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Corstasis Therapeutics

    U.S.A arrow
    Cancer Research
    Not Confirmed

    Corstasis Therapeutics

    U.S.A arrow
    Cancer Research
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Bumetanide

    Therapeutic Area : Cardiology/Vascular Diseases

    Study Phase : Phase III

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Corstasis' FDA-Approved Bumetanide Nasal Spray NDA

    Details : RSQ-777 (bumetanide is given to help treat edema and swelling that is caused by congestive heart failure, liver disease, kidney disease, or other medical conditions.

    Product Name : RSQ-777

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    January 27, 2025

    Lead Product(s) : Bumetanide

    Therapeutic Area : Cardiology/Vascular Diseases

    Highest Development Status : Phase III

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    Lupin Ltd

    India arrow
    Cancer Research
    Not Confirmed

    Lupin Ltd

    India arrow
    Cancer Research
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Bumetanide

    Therapeutic Area : Cardiology/Vascular Diseases

    Study Phase : Approved

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Lupin Launches Bumetanide Injection USP in US

    Details : Bumetanide injection generic version of Bumex, is given to help treat edema and swelling that is caused by congestive heart failure, liver disease, kidney disease, or other medical conditions.

    Product Name : Bumex-Generic

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    November 19, 2024

    Lead Product(s) : Bumetanide

    Therapeutic Area : Cardiology/Vascular Diseases

    Highest Development Status : Approved

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    03

    Lupin Ltd

    India arrow
    Cancer Research
    Not Confirmed

    Lupin Ltd

    India arrow
    Cancer Research
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Bumetanide

    Therapeutic Area : Cardiology/Vascular Diseases

    Study Phase : Approved

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Lupin Gets US FDA Nod for Bumetanide Injection, USP

    Details : Bumex-Generic (bumetanide) is a loop diuretic. It is indicated for the treatment of edema associated with congestive heart failure, hepatic and renal disease, including the nephrotic syndrome.

    Product Name : Bumex-Generic

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    September 19, 2024

    Lead Product(s) : Bumetanide

    Therapeutic Area : Cardiology/Vascular Diseases

    Highest Development Status : Approved

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    04

    Stalicla

    Switzerland arrow
    Cancer Research
    Not Confirmed

    Stalicla

    Switzerland arrow
    Cancer Research
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Ibudilast,Bumetanide

    Therapeutic Area : Neurology

    Study Phase : Phase I

    Sponsor : SPRIM Global Investments

    Deal Size : $17.4 million

    Deal Type : Series B Financing

    DEALS_DEV arrow-down

    Stalicla Secures $17.4 Million Series B Financing for Precision Neuro Advancements

    Details : Proceeds will support Stalicla's phase 2 Autism Spectrum Disorder (ASD) trial for STP1, a fixed-dose combination of PDE4/3 inhibitor (ibudilast) and NKCC1 antagonist (bumetanide).

    Product Name : STP1

    Product Type : Small molecule

    Upfront Cash : Undisclosed

    January 16, 2024

    Lead Product(s) : Ibudilast,Bumetanide

    Therapeutic Area : Neurology

    Highest Development Status : Phase I

    Sponsor : SPRIM Global Investments

    Deal Size : $17.4 million

    Deal Type : Series B Financing

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    05

    Stalicla

    Switzerland arrow
    Cancer Research
    Not Confirmed

    Stalicla

    Switzerland arrow
    Cancer Research
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Ibudilast,Bumetanide

    Therapeutic Area : Neurology

    Study Phase : Phase I

    Sponsor : Firefly Neuroscience

    Deal Size : Undisclosed

    Deal Type : Partnership

    DEALS_DEV arrow-down

    STALICLA and Firefly Neuroscience Enter Partnership Agreement for the Development of Electroencephalogram (EEG...

    Details : STALICLA and Firefly will leverage their technological platforms including the DEPI and BNA platform respectively to further advance EEG validation in two upcoming Phase 2 clinical trials including STALICLA’s lead asset STP1, a tailored treatment candi...

    Product Name : STP1

    Product Type : Small molecule

    Upfront Cash : Undisclosed

    March 27, 2023

    Lead Product(s) : Ibudilast,Bumetanide

    Therapeutic Area : Neurology

    Highest Development Status : Phase I

    Sponsor : Firefly Neuroscience

    Deal Size : Undisclosed

    Deal Type : Partnership

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    06

    Glenmark Pharmaceuticals

    India arrow
    Immuno-Oncology 360
    Not Confirmed

    Glenmark Pharmaceuticals

    India arrow
    Immuno-Oncology 360
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Bumetanide

    Therapeutic Area : Nephrology

    Study Phase : Approved

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Glenmark Pharmaceuticals Launches Generic Version of Diuretic Bumetanide Injection

    Details : Bumetanide injection generic version of Bumex, is given to help treat fluid retention (edema) and swelling that is caused by congestive heart failure, liver disease, kidney disease, or other medical conditions.

    Product Name : Undisclosed

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    January 10, 2023

    Lead Product(s) : Bumetanide

    Therapeutic Area : Nephrology

    Highest Development Status : Approved

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth